Figure 3
Kaplan–Meier curves for disease-free survival after complete resection in patients with stage I lung adenocarcinoma who received PAC with uracil–tegafur (A), or did not receive any PAC (B). a: Cases lacking both myosin IIA and vimentin expression (non-relapse survival rate at 5 years: 100% in panels A and B). b: Cases negative for myosin IIA expression and positive for vimentin expression, or positive for myosin IIA and negative for vimentin expression (non-relapse survival rate at 5 years: 64.7% in panel A and 53.7% in panel B). c: Cases positive for both myosin IIA and vimentin expression (non-relapse survival rate at 5 years: 30.0% in panel A and 49.0% in panel B). In patients who did not receive adjuvant chemotherapy, there was a statistically significant difference in disease-free survival between those who were negative and those who were positive for both proteins (a–c: P=0.011). No significant difference in this respect was recognised in patients who received PAC with uracil–tegafur.
